(2S)-2-amino-4-({[(2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxy(2,3,4,5-13C4)oxolan-2-yl](13C)methyl}sulfanyl)butanoic acid

• ChemBase编号: 159573
• 分子式: C14H20N6O5S
• 平均质量: 389.37407419
• 单一同位素质量: 389.13836296
• SMILES: n1cnc2c(c1N)ncn2[13C@H]1[13C@@H]([13C@@H]([13C@H](O1)[13CH2]SCC[C@H](N)C(=O)O)O)O
• Canonical SMILES: OC(=O)[C@H](CCS[13CH2][13C@H]1O[13C@H]([13C@@H]([13C@@H]1O)O)n1cnc2c1ncnc2N)N
• InChI: InChI=1S/C14H20N6O5S/c15-6(14(23)24)1-2-26-3-7-9(21)10(22)13(25-7)20-5-19-8-11(16)17-4-18-12(8)20/h4-7,9-10,13,21-22H,1-3,15H2,(H,23,24)(H2,16,17,18)/t6-,7+,9+,10+,13+/m0/s1/i3+1,7+1,9+1,10+1,13+1
• InChIKey: ZJUKTBDSGOFHSH-PKJIWKIESA-N

名称和登记号

名称

• IUPAC标准名: (2S)-2-amino-4-({[(2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxy(2,3,4,5-^1^3C₄)oxolan-2-yl](^1^3C)methyl}sulfanyl)butanoic acid
• IUPAC传统名: (2S)-2-amino-4-({[(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxy(2,3,4,5-^1^3C₄)oxolan-2-yl](^1^3C)methyl}sulfanyl)butanoic acid
• 别名: S-(5'-Deoxyadenosin-5'-yl)-L-homocysteine-13C5; L-5'-S-(3-Amino-3-carboxypropyl)-5'-thioadenosine-13C5; Adenosyl-L-homocysteine-13C5; Adenosylhomocysteine-13C5; L-S-Adenosylhomocysteine-13C5; S-Adenosyl-L-homocysteine-13C5; S-Adenosylhomocysteine-13C5; S-(5'-Adenosyl)-L-homocysteine-13C5

登记号

• PubChem SID: 162253708
• PubChem CID: 71313043

理论计算性质

• Acid pKa: 1.8116993
• 质子受体: 10
• 质子供体: 5
• LogD (pH = 5.5): -4.137044
• LogD (pH = 7.4): -4.026673
• Log P: -4.0272307
• 摩尔折射率: 92.7235 cm^3
• 极化性: 36.396317 Å^3
• 极化表面积: 182.63 Å^2
• 可自由旋转的化学键: 7
• 里宾斯基五规则: true

详细说明

Toronto Research Chemicals - A291502

A novel labelled biomarker for predicting susceptibility of a subject to a mental or neurodegenerative disorder.

参考文献

• Chamberlin, M., et al.: J. Clin. Invest., 98, 1021 (1996)
• Zoccolella, S., et al.: Neurology, 70, 222 (1996)